UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Treatment with pembrolizumab in programmed death ligand 1–positive recurrent glioblastoma: Results from the multicohort phase 1 KEYNOTE‐028 trial

Cancer, 2021-05, Vol.127 (10), p.1620-1629

2021

Volltextzugriff (PDF)

Paracaspase MALT1 regulates glioma cell survival by controlling endo‐lysosome homeostasis

The EMBO journal, 2020-01, Vol.39 (1), p.e102030-n/a

2020

Volltextzugriff (PDF)

Safety and Efficacy of Pembrolizumab in Advanced, Programmed Death Ligand 1-Positive Cervical Cancer: Results From the Phase Ib KEYNOTE-028 Trial

Journal of clinical oncology, 2017-12, Vol.35 (36), p.4035-4041

2017

Volltextzugriff (PDF)

Mammary carcinoma: Comparative oncology between small animals and humans-New therapeutic tools

Reproduction in domestic animals, 2023-09, Vol.58 (S2), p.102-108

2023

Volltextzugriff (PDF)

Prevalence of Proton Pump Inhibitor Use Among Patients With Cancer

JAMA network open, 2021-06, Vol.4 (6), p.e2113739-e2113739

2021

Volltextzugriff (PDF)

Tumor clone dynamics in lethal prostate cancer

Science translational medicine, 2014-09, Vol.6 (254), p.254ra125

2014

Volltextzugriff (PDF)

Evaluating everolimus for the treatment of breast cancer

Expert opinion on pharmacotherapy, 2023-07, Vol.24 (10), p.1105-1111

2023

Volltextzugriff (PDF)

The von Willebrand factor stamps plasmatic extracellular vesicles from glioblastoma patients

Scientific reports, 2021-11, Vol.11 (1), p.22792-22792, Article 22792

2021

Volltextzugriff (PDF)

Survival outcomes of metastatic breast cancer patients by germline BRCA1/2 status in a large multicenter real‐world database

International journal of cancer, 2023-03, Vol.152 (5), p.921-931

2023

Volltextzugriff (PDF)

Clinical impact of CA-125 ELIMination rate constant K (KELIM) on surgical strategy in advanced serous ovarian cancer patients

International journal of gynecological cancer, 2024-04, Vol.34 (4), p.574-580

2024

Volltextzugriff (PDF)

Olaparib for the treatment of breast cancer

Expert opinion on investigational drugs, 2017-06, Vol.26 (6), p.751-759

2017

Volltextzugriff (PDF)

Opportunities and Obstacles to the Development of Health Data Warehouses in Hospitals in France: The Recent Experience of Comprehensive Cancer Centers

International journal of environmental research and public health, 2023-01, Vol.20 (2), p.1645

2023

Volltextzugriff (PDF)

Did the COVID-19 pandemic delay treatment for localized breast cancer patients? A multicenter study

PloS one, 2024-05, Vol.19 (5), p.e0304556

2024

Volltextzugriff (PDF)

Optimizing the Retrieval of the Vital Status of Cancer Patients for Health Data Warehouses by Using Open Government Data in France

International journal of environmental research and public health, 2022-04, Vol.19 (7), p.4272

2022

Volltextzugriff (PDF)

An Update on the Clinical Use of CDK4/6 Inhibitors in Breast Cancer

Drugs (New York, N.Y.), 2018-09, Vol.78 (13), p.1353-1362

2018

Volltextzugriff (PDF)

Patient-centered simulations to assess the usefulness of the 70-gene signature for adjuvant chemotherapy administration in early-stage breast cancer

Breast cancer research and treatment, 2019-04, Vol.174 (2), p.537-542

2019

Volltextzugriff (PDF)

Genomic signature to guide adjuvant chemotherapy treatment decisions for early breast cancer patients in France: a cost-effectiveness analysis

Frontiers in oncology, 2023-06, Vol.13, p.1191943-1191943

2023

Volltextzugriff (PDF)

The predictive value of patient-reported outcomes on the impact of breast cancer treatment-related quality of life

Frontiers in oncology, 2022-10, Vol.12, p.925534-925534

2022

Volltextzugriff (PDF)

Pertuzumab for the treatment of breast cancer

Expert review of anticancer therapy, 2020-02, Vol.20 (2), p.85-95

2020

Volltextzugriff (PDF)

Pharmacokinetic drug evaluation of abemaciclib for advanced breast cancer

Expert opinion on drug metabolism & toxicology, 2019-02, Vol.15 (2), p.85-91

2019

Volltextzugriff (PDF)

Defining EGFR amplification status for clinical trial inclusion

Neuro-oncology (Charlottesville, Va.), 2019-10, Vol.21 (10), p.1263-1272

2019

Volltextzugriff (PDF)

Long-Term Use of Proton Pump Inhibitors in Cancer Patients: An Opinion Paper

Cancers, 2022-02, Vol.14 (5), p.1156

2022

Volltextzugriff (PDF)

Emerging PARP inhibitors for treating breast cancer

Expert opinion on emerging drugs, 2018-07, Vol.23 (3), p.211-221

2018

Volltextzugriff (PDF)

Functional pre-therapeutic evaluation by genome editing of variants of uncertain significance of essential tumor suppressor genes

Genome medicine, 2021-11, Vol.13 (1), p.174-174, Article 174

2021

Volltextzugriff (PDF)

1 – 25 von 221

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(216)
Mit Volltextzugriff
(175)

Publikationsform

Sprache

Englisch
(201)
Französisch
(22)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Treatment with pembrolizumab in programmed death ligand 1–positive recurrent glioblastoma: Results from the multicohort phase 1 KEYNOTE‐028 trial

Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial

Paracaspase MALT1 regulates glioma cell survival by controlling endo‐lysosome homeostasis

Safety and Efficacy of Pembrolizumab in Advanced, Programmed Death Ligand 1-Positive Cervical Cancer: Results From the Phase Ib KEYNOTE-028 Trial

Mammary carcinoma: Comparative oncology between small animals and humans-New therapeutic tools

Prevalence of Proton Pump Inhibitor Use Among Patients With Cancer

Tumor clone dynamics in lethal prostate cancer

Evaluating everolimus for the treatment of breast cancer

The von Willebrand factor stamps plasmatic extracellular vesicles from glioblastoma patients

Survival outcomes of metastatic breast cancer patients by germline BRCA1/2 status in a large multicenter real‐world database

Clinical impact of CA-125 ELIMination rate constant K (KELIM) on surgical strategy in advanced serous ovarian cancer patients

Olaparib for the treatment of breast cancer

Opportunities and Obstacles to the Development of Health Data Warehouses in Hospitals in France: The Recent Experience of Comprehensive Cancer Centers

Did the COVID-19 pandemic delay treatment for localized breast cancer patients? A multicenter study

Optimizing the Retrieval of the Vital Status of Cancer Patients for Health Data Warehouses by Using Open Government Data in France

An Update on the Clinical Use of CDK4/6 Inhibitors in Breast Cancer

Patient-centered simulations to assess the usefulness of the 70-gene signature for adjuvant chemotherapy administration in early-stage breast cancer

Genomic signature to guide adjuvant chemotherapy treatment decisions for early breast cancer patients in France: a cost-effectiveness analysis

The predictive value of patient-reported outcomes on the impact of breast cancer treatment-related quality of life

Pertuzumab for the treatment of breast cancer

Pharmacokinetic drug evaluation of abemaciclib for advanced breast cancer

Defining EGFR amplification status for clinical trial inclusion

Long-Term Use of Proton Pump Inhibitors in Cancer Patients: An Opinion Paper

Emerging PARP inhibitors for treating breast cancer

Functional pre-therapeutic evaluation by genome editing of variants of uncertain significance of essential tumor suppressor genes

Suchergebnisse filtern